Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer

@inproceedings{Lin2014CirculatingMA,
  title={Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer},
  author={H-M Lin and Lilian Castillo and Kate L. Mahon and Karen Chiam and Brian Y Lee and Q Nguyen and Michael J. Boyer and Martin Richard Stockler and Nick Pavlakis and Gavin Marx and Girish Mallesara and Howard Gurney and Susan J. Clark and Alexander Swarbrick and Roger J. Daly and Lisa G. Horvath},
  booktitle={British Journal of Cancer},
  year={2014}
}
Background:Docetaxel is the first-line chemotherapy for castration-resistant prostate cancer (CRPC). However, response rates are ∼50% and determined quite late in the treatment schedule, thus non-responders are subjected to unnecessary toxicity. The potential of circulating microRNAs as early biomarkers of docetaxel response in CRPC patients was investigated in this study.Methods:Global microRNA profiling was performed on docetaxel-resistant and sensitive cell lines to identify candidate… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 42 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

cancer and potential predictive factor for the efficacy of docetaxel - based chemotherapy

  • L Zhao, BY Lee, +10 authors LG Horvath
  • 2009
Highly Influential
4 Excerpts

MicroRNAs 17 - 5 p20 a - 106 a control monocytopoiesis through AML 1 targeting and M - CSF receptor upregulation

  • L Fontana, E Pelosi, +7 authors C Peschle
  • Nat Cell Biol
  • 2007
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…